Defendant
1 case as defendant.
Owner of US7704721 is not an operating company with a public profile, but rather an entity identified by its ownership of US Patent 7,704,721. This patent, titled "Injectable controlled release fluid delivery system," describes material delivery devices and systems for introducing materials into an animal body, particularly intelligently-controlled systems capable of long-term, in vivo material delivery and external loading.
The entity's patent litigation posture indicates it is a non-practicing entity (NPE) or patent assertion entity. The sole tracked case, Unified Patents Inc. v. Owner of US7704721, shows the entity as a defendant in a Patent Trial and Appeal Board (PTAB) proceeding. This strongly suggests that Owner of US7704721 is asserting its patent against operating companies, and Unified Patents, a membership organization dedicated to deterring NPE litigation, has filed an inter partes review (IPR) to challenge the validity of US7704721. Unified Patents' business model involves challenging patents owned by NPEs to reduce frivolous patent litigation against its members.
The specific patent, US7704721, focuses on medical or veterinary science, particularly devices for introducing or retaining media in body cavities. The case context suggests that Owner of US7704721 is likely attempting to license or assert this patent against companies involved in related medical device or drug delivery technologies.
An Inter Partes Review (IPR) challenging the validity of US patent 7704721 was filed by Unified Patents Inc. against the patent owner. The PTAB issued a decision of 'Not Instituted - Procedural'.